Advertisement

The European Journal of Health Economics

, Volume 17, Issue 3, pp 287–304 | Cite as

A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective

  • Keith Tolley
  • Danny Kemmett
  • Signe Thybo
  • Ruth Nasr
  • Helen Smethurst
Original Paper

Abstract

Background

Actinic keratosis (AK) is a UV-induced, pre-malignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line treatment for AK in Scotland is currently diclofenac gel (3 %). Ingenol mebutate gel is a recently developed topical therapy available in two strengths for the treatment of AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days).

Objective

To compare the cost-effectiveness of two strengths of ingenol mebutate gel developed to treat AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days) with other first-line AK therapies including diclofenac gel, 5-FU, 5-FU/salicylic acid, and cryotherapy for the first-line treatment of AK in adult patients, from the perspective of the National Health Service (NHS) in Scotland.

Methods

A cost-utility analysis was conducted using a decision-tree approach to calculate the costs and benefits of different treatment strategies for AK on the face and scalp or trunk and limbs over a 12-month time horizon. Data on the relative efficacy of treatments were obtained from a systematic literature review and meta-analysis. Utility scores and resource-use data were obtained from published sources.

Results

Over 12 months, ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were cost-effective compared with the most commonly used topical therapy in Scotland, diclofenac (3 %) gel, at a willingness-to-pay threshold of £20,000 per QALY, with a minimal additional cost of £43 and £105, respectively per QALY gained.

Conclusions

Ingenol mebutate gel is a cost-effective therapy for the first-line treatment of AK from a Scottish NHS perspective.

Keywords

Ingenol mebutate gel Actinic keratosis Cost-effectiveness ICER 

Notes

Acknowledgments

This study was funded by LEO Pharma.

Supplementary material

10198_2015_679_MOESM1_ESM.docx (60 kb)
Supplementary material 1 (DOCX 59 kb)
10198_2015_679_MOESM2_ESM.docx (49 kb)
Supplementary material 2 (DOCX 49 kb)

References

  1. 1.
    Marks, R., Foley, P., Goodman, G., Hage, B.H., Selwood, T.S.: Spontaneous remission of solar keratoses: the case for conservative management. Br. J. Dermatol. 115(6), 649–655 (1986)CrossRefPubMedGoogle Scholar
  2. 2.
    Primary Care Dermatology Society: Actinic keratosis (syn. solar keratosis). http://www.pcds.org.uk/image-atlas/a-z-of-diagnosis/50-image-atlas-detailed-articles/73-actinic-keratosis (2010)
  3. 3.
    Harvey, I., Frankel, S., Marks, R., Shalom, D., Nolan-Farrell, M.: Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br. J. Cancer 74(8), 1302–1307 (1996)CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tinghog, G., Carlsson, P., Synnerstad, I., Rosdahl, I.: Societal cost of skin cancer in Sweden in 2005. Acta Derm. Venereol. 88(5), 467–473 (2008). doi: 10.2340/00015555-0523 CrossRefPubMedGoogle Scholar
  5. 5.
    Morris, S., Cox, B., Bosanquet, N.: Cost of skin cancer in England. European J. Health Econ. 10(3), 267–273 (2009). doi: 10.1007/s10198-008-0127-0 CrossRefGoogle Scholar
  6. 6.
    Cancer Research UK: Skin cancer mortality statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/mortality/#source14 (2013). Accessed July 2013
  7. 7.
    Criscione, V.D., Weinstock, M.A., Naylor, M.F., Luque, C., Eide, M.J., Bingham, S.F.: Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial. Cancer 115(11), 2523–2530 (2009). doi: 10.1002/cncr.24284 CrossRefPubMedGoogle Scholar
  8. 8.
    Einspahr, J.G., Stratton, S.P., Bowden, G.T., Alberts, D.S.: Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 41(3):269–285 (2002). pii: S1040842801001858Google Scholar
  9. 9.
    Feldman, S.R., Fleischer Jr, A.B.: Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 87(4), 201–207 (2011)PubMedGoogle Scholar
  10. 10.
    Scottish Medicines Consortium: Imiquimod 5% cream (Aldara®). Meda Pharmaceuticals. SMC No. (385/07). http://www.scottishmedicines.org.uk/SMC_Advice/Advice/385_07_imiquimod_cream__Aldara_/imiquimod_cream__Aldara_ (2008). Accessed July 2013
  11. 11.
    Scottish Medicines Consortium (SMC): Methyl aminolevulinate 160 mg/g cream (Metvix®). Galderma Ltd. SMC No. (50/03) Available at: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/Methyl_amonolevulinate__Metvix_cream__174___for_actinic_keratoses/Methyl_aminolevulinate__Metvix_cream__ (2003). Accessed July 2013
  12. 12.
    Scottish Medicines Consortium: 5-aminolaevulinic acid (as hydrochloride), 78 mg/g, gel (Ameluz®). SMC No. (811/12) (2012)Google Scholar
  13. 13.
    NHS Scotland, S.D.S.: Solar (Actinic) keratoses and Bowen’s disease. Dermatology referral and management pathway (2010)Google Scholar
  14. 14.
    eMC: Summary of Product Characteristics: Actikerall 5 mg/g + 100 mg/g Cutaneous Solution. http://www.medicines.org.uk/EMC/medicine/24614/SPC/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution/ (2011). Accessed July 2013
  15. 15.
    eMC: Summary of Product Characteristics: Solaraze. http://www.medicines.org.uk/emc/medicine/21229) (2012). Accessed July 2013
  16. 16.
    eMC: Summary of Product Characteristics: Efudix Cream. http://www.medicines.org.uk/emc/medicine/6219/SPC/Efudix+Cream/ (2011). Accessed July 2013
  17. 17.
    Yentzer, B., Hick, J., Williams, L., Inabinet, R., Wilson, R., Camacho, F.T., Russell, G.B., Feldman, S.R.: Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch. Dermatol. 145(2), 203–205 (2009)CrossRefPubMedGoogle Scholar
  18. 18.
    Wilson, E.C.: Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 28(11), 1055–1064 (2010)CrossRefPubMedGoogle Scholar
  19. 19.
    Jeffes, E.W., McCullough, J.L., Weinstein, G.D., Fergin, P.E., Nelson, J.S., Shull, T.F., Simpson, K.R., Bukaty, L.M., Hoffman, W.L., Fong, N.L.: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133(6), 727–732 (1997)CrossRefPubMedGoogle Scholar
  20. 20.
    Taub, A.F., Garretson, C.B.: A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J. Drugs Dermatol. 10(9), 1049–1056 (2011)PubMedGoogle Scholar
  21. 21.
    Szeimies, R.M., Karrer, S., Sauerwald, A., Landthaler, M.: Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192(3), 246–251 (1996)CrossRefPubMedGoogle Scholar
  22. 22.
    Ulrich, M., Völker-Call, M., Lange-Asschenfeldt, S., Röwert-Huber, J., Østerdal, M.L., Skak, K., Skov, T., Stockfleth, E.: Biological effects of ingenol mebutate gel, 0.05%, for the treatment of actinic keratosis as assessed by reflectance confocal microscopy. Poster presented at American Academy of Dermatology Summer Academy Meeting Aug 15–19 2012, Boston, MA. USA. (2) (2012)Google Scholar
  23. 23.
    Lebwohl, M., Swanson, N., Anderson, L.L., Melgaard, A., Xu, Z., Berman, B.: Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 366(11), 1010–1019 (2012)CrossRefPubMedGoogle Scholar
  24. 24.
    Muston, D., Downs, A., Rives, V.: An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 20(5), 266–275 (2009)CrossRefPubMedGoogle Scholar
  25. 25.
    ISD Scotland: Prescription Cost Analysis for financial year 2011/12. http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/data-tables.asp (2012)
  26. 26.
    Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E.: NICE DSU technical support document 5: Evidence synthesis in the baseline natural history model. http://www.nicedsu.org.uk/TSD5%20Baseline.final%20report.08.05.12.pdf (2011)
  27. 27.
    Krawtchenko, N., Roewert-Huber, J., Ulrich, M., Mann, I., Sterry, W., Stockfleth, E.: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl 2), 34–40 (2007)CrossRefPubMedGoogle Scholar
  28. 28.
    eMC: Summary of Product Characteristics: Picato 150 mcg/g Gel. http://www.medicines.org.uk/emc/medicine/27246/SPC/Picato+150+mcg+g+Gel/ (2012). Accessed July 2013
  29. 29.
    Stockfleth, E., Kerl, H., Zwingers, T., Willers, C.: Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101–1108 (2011)CrossRefPubMedGoogle Scholar
  30. 30.
    Littenberg, B., Partilo, S., Licata, A., Kattan, M.W.: Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med. Decis. Making 23(6), 480–488 (2003). doi: 10.1177/0272989X03259817 CrossRefPubMedGoogle Scholar
  31. 31.
    Chen, S.C., Bayoumi, A.M., Soon, S.L., Aftergut, K., Cruz, P., Sexton, S.A., McCall, C.O., Goldstein, M.K.: A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9(2), 160–168 (2004). doi: 10.1046/j.1087-0024.2003.09112.x CrossRefPubMedGoogle Scholar
  32. 32.
    MIMS: Monthly Index of Medical Specialities (MIMS). Haymarket Medical Media, London (July 2012)Google Scholar
  33. 33.
    Thomas, K.S., Keogh-Brown, M.R., Chalmers, J.R., Fordham, R.J., Holland, R.C., Armstrong, S.J., Bachmann, M.O., Howe, A.H., Rodgers, S., Avery, A.J., Harvey, I., Williams, H.C.: Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. Health Technol Assess 10(25), iii, ix-87 (2006). doi:02-12-03 [pii]Google Scholar
  34. 34.
    Curtis, L.: Unit Costs of Health and Social Care 2011. Personal Social Services Research Unit, Canterbury (2011)Google Scholar
  35. 35.
    ISD Scotland: Acute medical costs R044X: Specialty group costs—consultant outpatients (2011)Google Scholar
  36. 36.
    Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479–500 (2000)CrossRefPubMedGoogle Scholar
  37. 37.
    Briggs, A.H., O’Brien, B.J., Blackhouse, G.: Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu. Rev. Public Health 23, 377–401 (2002)CrossRefPubMedGoogle Scholar
  38. 38.
    Scottish Medicines Consortium: ingenol mebutate, 150 & 500micrograms/g, gel (Picato®) SMC No. (851/13). http://www.scottishmedicines.org.uk/files/advice/ingenol_mebutate_gel_Picato_FINAL_FEBRUARY_2013_amended_04.03.13_for_website.pdf (2013). Accessed Aug 2013
  39. 39.
    Scottish Medicines Consortium: Guidance to manufacturers for completion of New Product Assessment Form (NPAF). (2012)Google Scholar
  40. 40.
    Jorizzo, J., Dinehart, S., Matheson, R., Moore, J.K., Ling, M., Fox, T.L., McRae, S., Fielder, S., Lee, J.H.: Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J. Am. Acad. Dermatol. 57(2), 265–268 (2007)CrossRefPubMedGoogle Scholar
  41. 41.
    Gebauer, K., Brown, P., Varigos, G.: Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas. J. Dermatol. 44(1), 40–43 (2003)CrossRefPubMedGoogle Scholar
  42. 42.
    Weinstock, M.A., Lee, K.C., Chren, M.M., Marcolivio, K.: Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J. Am. Acad. Dermatol. 61(2), 207–215 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    European Dermatology Forum: Guideline on Actinic Keratoses (update) (2011)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Keith Tolley
    • 1
  • Danny Kemmett
    • 2
  • Signe Thybo
    • 3
  • Ruth Nasr
    • 3
  • Helen Smethurst
    • 4
  1. 1.Tolley Health EconomicsBuxtonUK
  2. 2.Department of DermatologyVale of Leven HospitalAlexandriaUK
  3. 3.LEO PharmaHurleyUK
  4. 4.Abacus InternationalBicesterUK

Personalised recommendations